Monday, the 3rd of August wasn’t a good day at the market for CERUS when it faced a loss and saw that its shares dipped really low by -4.05% which caused the prices of its shares to be closed at a cost of $5.21.

The dip was quite surprising since the company recently announced that Unyts, which the provider of blood components has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. The recent agreement signer is a provider of this services to more than eight counties in the West part of The Big Apple. It has its supplies of supplying about 11,000 plasma units and about five thousand platelets on a yearly basis.

The company is a renowned biomedical products company which mostlyemphases and pays attention on developing INTERCEPT Blood System to enhance blood safety. It thrives to provide blood transfusion safety and has enrolled itself in developing programs for awareness also.

Agenus on the other hand also saw quite a bit of low point in the market. The company saw a loss at the market of -3.28% which caused the shares to be sold at a price of $8.26. The market also closed at this price as well.

The dip shouldn’t have come since recently the company announced that that it had received a positive response from GlaxoSmithKline (GSK) for its Malaria vaccine candidate. The positive response was also received by the Committee fort Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The vaccine candidate has been named Mosquirix™ (RTS,S) which is the first product to have QS-21 Stimulon that has received a positive regulatory decision up until now. Agenus’ adjuvant QS-21 has been developed and made keeping in mind one purpose: to enrich immune response to antigens in vaccines. The positive opinion gives a green signal that Mosquirix meets the essential and compulsoryefficacy, safety and quality requirements that have been set by the European Union.

Agenus is a biotechnology company which is based in Massachusetts. It focuses primarily on immunotherapy.

Micrel also suffered the same fate as the top two companies. On Monday, it saw a dip in the market as well. The company suffered a loss of -0.65% which caused the closing of its shares to occur at a price of $13.86.

The company recently announced that Microchip has accomplished its formerly declared acquisition of Micrel. Micrel will be giving 98.95% of the Micrel to Microchip which have been voted as per their stock holders. Because of the merger the trading in Micrel common stock on the NASDAQ Stock Market will stop as soon as possible.

Micrel was founded in 1978 and has its headquarters in California and San Diego. It is responsible for developing, manufacturing and designing mixed-signal and digital semiconductor devices in Asia, Europe and in North America.



Please enter your comment!
Please enter your name here